8-K: Disc Medicine Announces Positive Clinical Data and Secures $178 Million in Funding

Disc Medicine reported positive clinical data across its pipeline and strengthened its financial position with a $178 million capital raise.

Summary

• Disc Medicine announced its second quarter 2024 financial results and provided a business update.
• The company presented positive data for all three of its programs at the European Hematology Association (EHA) 2024 Congress.
• Bitopertin showed potential efficacy in erythropoietic protoporphyria (EPP).
• DISC-0974 demonstrated a durable hemoglobin response in patients with anemia of myelofibrosis (MF).
• DISC-3405 showed proof of mechanism in a Phase 1 study with substantial increases in hepcidin levels.
• Disc Medicine plans to provide updates on regulatory interactions for bitopertin and DISC-0974 in the second half of 2024.
• The company completed an underwritten offering of common stock for $178 million in gross proceeds.
• Disc Medicine ended the second quarter with $501 million in cash, cash equivalents, and marketable securities, which is expected to fund operations well into 2027.
• Research and development expenses were $23.5 million for the quarter ended June 30, 2024, compared to $12.1 million for the same period in 2023.
• General and administrative expenses were $7.4 million for the quarter ended June 30, 2024, compared to $5.2 million for the same period in 2023.
• The net loss for the quarter ended June 30, 2024, was $26.4 million, compared to a net loss of $15.9 million for the same period in 2023.

Sentiment

Score: 8

Explanation: The document is positive due to the successful capital raise, positive clinical data, and strong cash position. However, the increased expenses and net loss temper the overall sentiment slightly.

Positives

• Positive clinical data was presented for all three programs at the EHA 2024 Congress.
• The company successfully completed a $178 million capital raise.
• The company has a strong cash position of $501 million, providing a long operational runway.
• Bitopertin showed promising efficacy in EPP.
• DISC-0974 demonstrated a positive impact on hemoglobin levels and transfusion burden in MF patients.
• DISC-3405 showed proof of mechanism with significant increases in hepcidin levels.

Negatives

• The company reported a net loss of $26.4 million for the second quarter of 2024, which is higher than the $15.9 million loss in the same period of 2023.
• Research and development expenses increased significantly to $23.5 million in Q2 2024, compared to $12.1 million in Q2 2023.
• General and administrative expenses also increased to $7.4 million in Q2 2024, compared to $5.2 million in Q2 2023.

Risks

• The company's future success depends on the successful development and commercialization of its product candidates.
• Clinical trial results may not be predictive of future results.
• The company may face challenges in obtaining regulatory approvals for its product candidates.
• The company's operating expenses are increasing, which could impact its financial performance.
• The company's ability to fund operations is dependent on its cash reserves and future capital raises.

Future Outlook

The company expects its current cash position to fund operations well into 2027 and plans to provide updates on regulatory interactions for bitopertin and DISC-0974 in the second half of 2024. They also anticipate sharing updated data from various clinical trials in the second half of 2024.

Management Comments

• The data we presented at EHA this past quarter were highly encouraging and supportive of the therapeutic potential of our entire portfolio, said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.
• These data catalyzed the successful completion of a financing supported by a prestigious group of investors, which provides runway through key readouts across our programs over the next few years.
• We continue to make great progress and look forward to sharing updates on our regulatory interactions around bitopertin and DISC-0974 in the second half of the year.

Industry Context

This announcement is positive for Disc Medicine as it highlights progress in their clinical programs and secures funding to continue operations. The focus on hematologic diseases aligns with the growing interest in novel treatments for these conditions. The successful capital raise positions them well against competitors in the biotech space.

Comparison to Industry Standards

• The $178 million capital raise is significant for a clinical-stage biotech company, comparable to other successful financings in the sector, such as those by companies like Arcus Biosciences and Relay Therapeutics.
• The reported cash position of $501 million is strong and provides a runway similar to other well-funded biotech companies at this stage, such as Blueprint Medicines and Agios Pharmaceuticals.
• The increase in R&D expenses is typical for a company advancing multiple clinical programs, and the magnitude is in line with other companies in the clinical trial phase, such as Alnylam Pharmaceuticals and BioMarin Pharmaceutical.
• The net loss is also typical for a clinical-stage biotech company, and the increase is expected as the company progresses its programs, similar to companies like CRISPR Therapeutics and Editas Medicine.

Stakeholder Impact

• Shareholders benefit from the positive clinical data and the strengthened financial position.
• Employees may benefit from the company's growth and continued operations.
• Patients with hematologic diseases may benefit from the development of new treatments.
• Creditors are likely to view the company's financial stability positively.
• Suppliers may benefit from increased business with the company.

Next Steps

• The company plans to provide an update on regulatory interactions for bitopertin in EPP and DISC-0974 in anemia of MF in the second half of 2024.
• Updated Phase 1b data from DISC-0974 in anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) is expected to be shared in the second half of 2024.
• Data from the multiple ascending dose (MAD) cohorts of the DISC-3405 study is expected to be shared in the second half of 2024.
• An end of Phase 2 meeting to discuss optimal registrational endpoints for bitopertin in EPP is expected in the second half of 2024.
• The company plans for interactions with regulators in the second half of 2024 to determine the optimal Phase 2 study design in anemia of MF.

Key Dates

Keywords

Disc Medicine, Hematologic Diseases, Bitopertin, DISC-0974, DISC-3405, Erythropoietic Protoporphyria, Myelofibrosis, Anemia, Hepcidin, Clinical Trials, Capital Raise, Biopharmaceutical